CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Patrick J. Beyer CEO | XMUN Exchange | US2074101013 ISIN |
| US Country | 3,900 Employees | 15 Sep 2025 Last Dividend | 10 Sep 2001 Last Split | 23 Jul 1987 IPO Date |
CONMED Corporation is an influential player in the medical technology sphere, with a focus on the development, manufacturing, and global sales of surgical devices and related equipment. This company caters to a broad spectrum of surgical procedures, providing innovative solutions that aim to enhance clinical outcomes for patients around the world. Operating under various esteemed brands, including Hall, CONMED Linvatec, Concept, and Shutt, the corporation has established a strong reputation for quality and innovation since its inception in 1970. Headquartered in Largo, Florida, CONMED Corporation takes a direct approach to marketing its products, targeting hospitals, surgery centers, and other healthcare institutions while also leveraging medical specialty distributors for broader reach.